Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib

JAMA Dermatology

Volumn 149, Issue 5, 2013, Pages 624-626

  Jimeńez Gallo, David ^a   Albarrán Planelles, Cristina ^a   Linares Barrios, Mario ^a   Martińez Rodríguez, Alberto ^a   Báez Perea, José María ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SAFETY; EPILUMINESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; MALE; MELANOCYTIC NEVUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ERUPTIONS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEVUS, PIGMENTED; PYRROLES;

EID: 84877864149     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.263     Document Type: Article

References (6)

1. Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820-822. (Pubitemid 351846901)
2. Bennani-Lahlou M, Mateus C, Escudier B, et al. Eruptive nevi associated with sorafenib treatment [in French]. Ann Dermatol Venereol. 2008;135:672-674.
3. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24(4):396-400.
4. Karram S, Novy M, Saroufim M, et al. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure [published online October 9, 2012]. Am J Dermatopathol . doi:10.1097/DAD. 0b013e31826db181.
5. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720- 724. (Pubitemid 41117276)
6. Piscazzi A, Costantino E, Maddalena F, et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2012;97(6):E898-E906.